{"id":"NCT00539864","sponsor":"Protein Sciences Corporation","briefTitle":"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","officialTitle":"Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2007-10-05","resultsPosted":"2011-07-27","lastUpdate":"2011-07-27"},"enrollment":602,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"FluBlok Influenza Vaccination","otherNames":["FluBlok","rHA","rHA0","recombinant hemagglutinin"]},{"type":"BIOLOGICAL","name":"TIV (Fluzone) Influenza Vaccination","otherNames":["Fluzone","TIV"]}],"arms":[{"label":"FluBlok","type":"EXPERIMENTAL"},{"label":"TIV (Fluzone)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.","primaryOutcome":{"measure":"Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)","timeFrame":"Reactogenicity days 0-7 following immunization; other AEs days 0-28 following immunization","effectByArm":[{"arm":"FluBlok","deltaMin":40,"sd":null},{"arm":"TIV (Fluzone)","deltaMin":62,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["21277410"],"seeAlso":["http://proteinsciences.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":300},"commonTop":["Pharyngolaryngeal pain"]}}